STAT3 and Hepatic fibrosis: Moreover, research on Danshensu, a novel inhibitor of indoleamine 2,3-dioxygenase 1, has revealed that it inhibits JAK2-STAT3 signaling, resulting in reduced hepatic fibrosis 23.